Test whether rolipram retains working-memory / cognitive phenotype under Pde4b/Pde4d LOF or PDE4-matched blockade that abolishes PDE4-class attribution

Rolipram WM / object-recognition / LTP-linked cognition phenotypes are often framed as PDE4 orthosteric blockade, yet Barad is a late-LTP/memory phenotype prior, Zhang HT is a radial-arm WM phenotype prior, Rutten is an object-recognition phenotype prior, and Li is a PDE4D KO phenocopy plus cogn occlusion prior (rolipram WAS tested in 4DKO — no further memory enhance; honesty NOT residual-positive; AGAINST residual) — none score residual-positive under PDE4 abolish. This discussion asks whether any residual rolipram WM / cognitive phenotype survives a Pde4b/Pde4d LOF or PDE4-matched blockade that abolishes PDE4-class attribution on the same panel.

Claim

On a pre-registered acute/subacute rodent (Barad/Zhang HT/Rutten/Li-class) working-memory / object-recognition / LTP-linked cognition panel with a rolipram-alone arm, a PDE4 genetic LOF (Pde4b and/or Pde4d) or PDE4-matched blockade that abolishes PDE4-class attribution, and a rolipram-under-abolish arm: under the same condition that abolishes PDE4-class attribution, rolipram retains residual working-memory / cognitive phenotype ≥50% of rolipram-alone (WM / object-recognition / cognition units as pre-specified; α/N pre-specified) — assumption-kill / pde4-insufficiency.

Why it matters

Rolipram WM / object-recognition / LTP-linked cognition phenotypes are often framed as PDE4 orthosteric blockade; Barad is a late-LTP/memory phenotype prior, Zhang HT is a radial-arm WM phenotype prior, Rutten is an object-recognition phenotype prior, and Li is a PDE4D KO phenocopy plus cogn occlusion prior (rolipram WAS tested in 4DKO — no further memory enhance; honesty NOT residual-positive; AGAINST residual) — none score residual-positive under PDE4 abolish. N27 asks whether residual rolipram WM / cognitive phenotype survives a Pde4b/Pde4d LOF or PDE4-matched blockade that kills PDE4-class attribution — pde4-insufficiency assumption-kill. Especially distinct from N26 (fluoxetine residual under SERT genetic LOF / SERT-matched block — PDE4 ≠ SERT; rolipram ≠ fluoxetine); N25 (atomoxetine residual under NET genetic LOF / NET-matched block — PDE4 ≠ NET; rolipram ≠ atomoxetine); N24 (caffeine residual under Adora2a/A2A abolish — A2A ≠ PDE4); N23 (guanfacine residual under α2A LOF / α2-antagonist — α2 ≠ PDE4); N22 (tyrosine residual under AMPT — AMPT ≠ PDE4 LOF); N15 (modafinil residual under DAT-matched block — DAT ≠ PDE4); also N16–N21 ≠ N27; N2 holds sole ip_class=none; NOT MB/MAOI. Soft-claims: discussion — matched residual-rolipram under PDE4 abolish that abolishes PDE4-class attribution H2H UNKNOWN as residual-positive (Li occlusion FOUND AGAINST residual; Zhang 12377395 antidepressant necessity OUT of public prior_art); PRIOR_ART PARTIAL (necessity/occlusion FOUND; residual-positive under abolish absent; phenotype priors FOUND); soft-complete empty ≠ novelty / ≠ failure; N1–N26 ≠ proof.

Mechanism sketch

Pde4-insufficiency assumption-kill: rolipram moves WM / object-recognition / LTP-linked cognition phenotypes and is framed as selective PDE4 blockade, with Pde4d KO as a genetic tool (Li) and published phenotype priors (Barad late-LTP/memory; Zhang HT radial-arm WM; Rutten OR); no published head-to-head scores residual-positive rolipram WM / cognition under a Pde4b/Pde4d LOF or PDE4-matched blockade that abolishes PDE4-class attribution on the same panel as a retained residual ≥50% of rolipram-alone. Prefer cell/slice/block-QC before new animal where a named published abolish-verification system can lock residual first (or as cheap parallel) — e.g. hippocampal-slice LTP (Barad-class) or PDE activity QC for abolish gate; in vivo Barad/Zhang HT/Rutten/Li-class rodent WM / OR / cognition panel remains the primary kill path. Li 21209202 is phenocopy + cogn occlusion (rolipram WAS tested IN 4DKO — memory enhancement in 4DKO not affected by chronic rolipram; rolipram did not alter memory in PDE4D-deficient mice) — do NOT misread as residual-positive; AGAINST residual-under-PDE4D-LOF. Zhang 12377395 (promoted; OUT of public prior_art) is antidepressant TST/FST necessity (rolipram effects only in PDE4D+/+) — AGAINST residual for that endpoint; not cogn residual H2H. Wang 23003922 (promoted; OUT of public prior_art) is adjacent PDE4D-shRNA cogn/antidep occlusion (effects not enhanced by rolipram) — AGAINST residual misread. Phenotype priors (Barad 9844008; Zhang HT 10923759; Rutten 16242977) lack residual-under-PDE4-abolish arms — PRIOR_ART PARTIAL; do not invent residual-positive H2H; do not treat Li as residual-positive; do not treat Zhang antidepressant necessity as cogn residual; do not collapse to N26 SERT or N25 NET. Competing caveats: abolish condition fails to kill PDE4-class attribution / rolipram-alone null / underpowered strata / assay-identity mismatch (phenotype ≠ residual; phenocopy ≠ residual-under-abolish; antidepressant TST/FST ≠ cogn panel; occlusion ≠ residual-positive; SERT ≠ PDE4; NET ≠ PDE4) leave the test inconclusive rather than refuted; soft-complete empty ≠ novelty / ≠ residual-gain proof; N15 ≠ this (DAT ≠ PDE4); N16 ≠ this; N17 ≠ this; N18 ≠ this; N19 ≠ this; N20 ≠ this; N21 ≠ this; N22 ≠ this (AMPT ≠ PDE4 LOF); N23 ≠ this (α2 ≠ PDE4); N24 ≠ this (A2A ≠ PDE4); N25 ≠ this (NET ≠ PDE4; atomoxetine ≠ rolipram); N26 ≠ this (SERT ≠ PDE4; fluoxetine ≠ rolipram). NOT MB/MAOI (SERIES_FROZEN).

Prior art

• PMID 9844008 / DOI 10.1073/pnas.95.25.15020 — Barad: rolipram facilitates late-LTP (CA1 after single tetanus) and improves long-term contextual freezing in young/aged mice (PNAS 1998) — LTP/memory phenotype prior; WT PDE4 present; no PDE4-abolish residual arm. doi.org HEAD 302 (PMC24568).
• PMID 10923759 / DOI 10.1007/s002130000414 — Zhang HT: rolipram reverses scopolamine-induced working and reference memory errors (radial-arm maze) (Psychopharmacology 2000) — WM phenotype prior; WT PDE4 present; no PDE4-abolish residual arm. doi.org HEAD 302 (PubMed DOI verified).
• PMID 16242977 / DOI 10.1016/j.nlm.2005.09.002 — Rutten: rolipram reverses scopolamine- and time-dependent object-recognition deficits (Neurobiol Learn Mem 2006) — OR phenotype prior; WT PDE4 present; no PDE4-abolish residual arm. doi.org HEAD 302 (PubMed DOI verified).
• PMID 21209202 / DOI 10.1523/JNEUROSCI.5236-10.2011 — Li: PDE4D KO / RNAi enhance memory (radial-arm, water maze, object recognition) and hippocampal neurogenesis; mimicked by rolipram in WT (phenocopy). CRITICAL: rolipram WAS tested IN 4DKO — memory enhancement in 4DKO not affected by chronic rolipram; rolipram did not alter memory in PDE4D-deficient mice — cogn occlusion / necessity AGAINST residual; honesty NOT residual-positive (J Neurosci 2011). doi.org HEAD 302 (PMC3079568).

Baseline claimed

Under PDE4 genetic LOF (Pde4b and/or Pde4d) or PDE4-matched blockade that abolishes PDE4-class attribution, rolipram still retains working-memory / cognitive phenotype on the same panel — or Li 21209202 already proves residual rolipram under PDE4D abolish — or Barad LTP/memory / Zhang HT radial-arm WM / Rutten OR already constitute residual-under-abolish H2H — or Zhang 12377395 TST/FST abolish already is cogn residual — or Wang 23003922 PDE4D-shRNA occlusion already is residual-positive — or N15 modafinil-DAT / N16 plasma-Cr/PCr / N17 Hericium-NGF/TrkA / N18 theanine-adenosine / N19 Rhodiola-HPA / N20 Bacopa-AChE / N21 nicotine-nAChR / N22 tyrosine-AMPT / N23 guanfacine-alpha2 / N24 caffeine-A2A / N25 atomoxetine-NET / N26 fluoxetine-SERT / N1–N26 already settle residual rolipram under PDE4 abolish.

Baseline measured

Barad late-LTP/memory LITERATURE phenotype prior without PDE4-abolish residual arm (PMID 9844008). Zhang HT radial-arm WM LITERATURE phenotype prior without PDE4-abolish residual arm (PMID 10923759). Rutten object-recognition LITERATURE phenotype prior without PDE4-abolish residual arm (PMID 16242977). Li PDE4D KO phenocopy + cogn occlusion LITERATURE — rolipram WAS tested IN 4DKO; no further memory enhance; honesty NOT residual-positive; AGAINST residual (PMID 21209202). Zhang 12377395 rolipram antidepressant TST/FST effects only in PDE4D+/+ LITERATURE promoted antidepressant necessity AGAINST residual for that endpoint; not cogn residual H2H (OUT of public prior_art; baseline_measured/mechanism OK). Wang 23003922 PDE4D-shRNA cogn/antidep effects not enhanced by rolipram LITERATURE promoted adjacent occlusion AGAINST residual misread (OUT of public prior_art; baseline_measured/mechanism OK). Matched residual-positive rolipram under Pde4b/Pde4d LOF or PDE4-matched block that abolishes PDE4-class attribution UNKNOWN as residual-positive (soft-complete Q_resid_tight=1 REVIEW NON-MATCH residual-positive experimental; Li occlusion FOUND AGAINST residual; phenotype ≠ residual; phenocopy ≠ residual-positive; antidepressant ≠ cogn). Residual rolipram phenotype ≥50% of rolipram-alone when PDE4-class attribution abolished PREDICTION. N15 ≠ N27 (DAT ≠ PDE4); N16 ≠ N27; N17 ≠ N27; N18 ≠ N27; N19 ≠ N27; N20 ≠ N27; N21 ≠ N27; N22 ≠ N27 (AMPT ≠ PDE4 LOF); N23 ≠ N27 (α2 ≠ PDE4); N24 ≠ N27 (A2A ≠ PDE4); N25 ≠ N27 (NET ≠ PDE4; atomoxetine ≠ rolipram); N26 ≠ N27 (SERT ≠ PDE4; fluoxetine ≠ rolipram); N1–N26 ≠ proof — soft-complete empty ≠ novelty / ≠ residual-gain proof; do not invent residual; do not treat Li as residual-positive; do not treat Zhang antidepressant as cogn residual; do not invent residual-positive from occlusion.

Actionable limitations

1. Do not treat N1–N26 as proving N27 — especially N26 ≠ N27 (PDE4 ≠ SERT; rolipram ≠ fluoxetine); N25 ≠ N27 (PDE4 ≠ NET; rolipram ≠ atomoxetine); N24 ≠ N27 (A2A ≠ PDE4); N23 ≠ N27 (α2 ≠ PDE4); N22 ≠ N27 (AMPT ≠ PDE4 LOF); N15 ≠ N27 (DAT ≠ PDE4); N16 is plasma-Cr↑ without ³¹P PCr fails SD WM; N17 is Hericium residual under NGF/TrkA block; N18 is L-theanine residual under caffeine-matched adenosine; N19 is Rhodiola residual under HPA/cortisol-matched; N20 is Bacopa residual under donepezil/AChE occupancy match; N21 is nicotine residual under mecamylamine/nAChR block; soft-complete empty ≠ demonstrated residual gain.
2. Necessity/occlusion FOUND — Li 21209202 constrains PDE4 bridge (rolipram-in-4DKO no further memory enhance; AGAINST residual) — PRIOR_ART PARTIAL OK, not auto-REJECT; do not invent residual-positive H2H; do not treat Li as residual-positive; do not treat Zhang 12377395 TST/FST necessity as cogn residual; do not treat Wang 23003922 as residual-positive. Phenotype ≠ residual — Barad 9844008; Zhang HT 10923759; Rutten 16242977 lack residual-under-PDE4-abolish arms.
3. Prefer cell/slice/block-QC before new animal; lock same-panel acute/subacute rodent (Barad/Zhang HT/Rutten/Li-class) WM / OR / LTP-linked cognition with rolipram ± Pde4b/Pde4d LOF or PDE4-matched challenge as primary kill path; no dosing; NOT MB/MAOI; not N15–N26 clones; orthosteric_drift=false; do not burn ip_class=none; do not collapse to N26 SERT or N25 NET.

Method

propose-assay

Labels

status_labels: [NEGATIVE] novelty_tag: assumption-kill polarity: negative openlabs_target: discussion openlabs_topic: neuroscience-brain tags: nootropics, brain-longevity risk_class: research-discussion

Prediction variables

Ablate

• remove same-panel contrast of residual rolipram WM / cognitive phenotype under Pde4b/Pde4d LOF or PDE4-matched blockade that abolishes PDE4-class attribution: Without the abolish×residual H2H on a Barad/Zhang HT/Rutten/Li-class panel with a rolipram arm, separate phenocopy/occlusion LITERATURE and phenotype LITERATURE cannot show pde4-insufficiency as a residual-positive kill.
• remove verified abolish gate (Pde4b/Pde4d LOF or PDE4-matched blockade that abolishes PDE4-class attribution) plus rolipram-alone comparator as the residual gate: Without verified PDE4-class abolish and rolipram-alone comparator under the same condition, residual rolipram is just “another cAMP agent under nonspecific challenge,” not an assumption-kill of PDE4-class sufficiency for the rolipram phenotype.
• remove N15≠N27 + N16≠N27 + N17≠N27 + N18≠N27 + N19≠N27 + N20≠N27 + N21≠N27 + N22≠N27 + N23≠N27 + N24≠N27 + N25≠N27 + N26≠N27 + N1–N26≠proof + soft-complete-empty≠novelty + phenotype≠residual + phenocopy≠residual + Li-not-residual-positive + Zhang-antidep≠cogn-residual + Wang≠residual-positive + NOT-MB/MAOI + ip_class≠none + orthosteric_drift=false discipline: Treating N15–N26 residuals (especially N26 SERT / N25 NET / N24 A2A / N23 α2 / N15 DAT as if they were PDE4 abolish), Li occlusion as residual-under-abolish, Zhang antidepressant necessity as cogn residual, Barad/Zhang HT/Rutten phenotype as residual H2H, or empty/adjacent PubMed as already deciding residual-positive rolipram under PDE4 abolish would invent an H2H result left UNKNOWN as residual-positive.

Refute if

On the pre-registered acute/subacute rodent (Barad/Zhang HT/Rutten/Li-class) working-memory / object-recognition / LTP-linked cognition panel, under Pde4b and/or Pde4d genetic LOF or a PDE4-matched blockade that abolishes PDE4-class attribution, residual rolipram WM / cognitive phenotype falls below 50% of rolipram-alone (WM / object-recognition / cognition units as pre-specified) — so PDE4-class sufficiency for the rolipram phenotype survives and pde4-insufficiency fails — when abolish-gate, rolipram-alone comparator, and power/assay artifacts that would otherwise leave the test inconclusive are ruled out.

Ask a human

Prefer cell/slice/block-QC before new animal; lock acute/subacute rodent (Barad/Zhang HT/Rutten/Li-class) WM / object-recognition / LTP-linked cognition assay identity, PDE4-class attribution abolish gate under Pde4b/Pde4d LOF or named PDE4-matched blockade, rolipram-alone comparator, and optional cell/slice/block-QC overlay only after abolish×residual locks; do not treat N15 or N16 or N17 or N18 or N19 or N20 or N21 or N22 or N23 or N24 or N25 or N26 or N1–N26 as proof — especially N26 ≠ N27 (PDE4 ≠ SERT; rolipram ≠ fluoxetine); N25 ≠ N27 (PDE4 ≠ NET; rolipram ≠ atomoxetine); N24 ≠ N27 (A2A ≠ PDE4); N23 ≠ N27 (α2 ≠ PDE4); N22 ≠ N27 (AMPT ≠ PDE4 LOF); N15 ≠ N27 (DAT ≠ PDE4); do not treat Li as residual-positive; do not treat Zhang antidepressant necessity as cogn residual; no dosing; NOT MB/MAOI; not N15 DAT clone; not N16 creatine clone; not N17 NGF/TrkA clone; not N18 theanine-adenosine clone; not N19 HPA/cortisol clone; not N20 Bacopa/AChE clone; not N21 nicotine/nAChR clone; not N22 tyrosine/AMPT clone; not N23 guanfacine/alpha2 clone; not N24 caffeine/A2A clone; not N25 atomoxetine/NET clone; not N26 fluoxetine/SERT clone; orthosteric_drift=false; do not burn ip_class=none; do not invent residual; do not invent residual-positive from occlusion.

Cheap IP

kill_cost_tier=1 · time_to_refute=4w · ip_class=pde4-insufficiency · vault_hold=no

Execution

execution_status=NOT_RUN · fto_status=UNKNOWN · related_prior=N15 (modafinil-DAT residual ≠ rolipram×PDE4; DAT ≠ PDE4); N16 (plasma-Cr/PCr ≠ rolipram×PDE4); N17 (Hericium×NGF/TrkA ≠ rolipram×PDE4); N18 (theanine-adenosine ≠ rolipram×PDE4); N19 (Rhodiola-HPA ≠ rolipram×PDE4); N20 (Bacopa×AChE ≠ rolipram×PDE4); N21 (nicotine×nAChR ≠ rolipram×PDE4); N22 (tyrosine/AMPT ≠ rolipram×PDE4; AMPT ≠ PDE4 LOF); N23 (guanfacine×alpha2 ≠ rolipram×PDE4; α2 ≠ PDE4); N24 (caffeine×A2A ≠ rolipram×PDE4); N25 (atomoxetine×NET ≠ rolipram×PDE4; PDE4 ≠ NET; rolipram ≠ atomoxetine; ESPECIALLY DISTINCT); N26 (fluoxetine×SERT ≠ rolipram×PDE4; PDE4 ≠ SERT; rolipram ≠ fluoxetine; ESPECIALLY DISTINCT); N2 holds sole ip_class=none; N1–N26 ≠ proof

Swarm metadata

STATUS_LABEL: NEGATIVE openlabs_target: discussion openlabs_topic: neuroscience-brain tags: nootropics, brain-longevity risk_class: research-discussion polarity: negative card: ~/hypothesis-swarm/cards/N27.card.md card_sha256: ea7053ac92335b7264d13c0f4320d6335a78eb63e655c6599eacfade27ccea5b

Mol Labs public report: PENDING dual-publish